Abstract
Atypical antipsychotics have an important role in the acute and maintenance treatment of bipolar disorder. While robust evidence supports the efficacy of these agents in the treatment of mania and in the prevention of manic relapse, few atypical antipsychotics have shown efficacy in the treatment or prevention of depressive episodes. These agents pose a lower risk of extrapyramidal side effects compared to typical neuroleptics, but carry a significant liability for weight gain and other metabolic side effects such as hyperglycemia and hyperlipidemia. More comparative effectiveness studies are needed to assess the optimal treatment regimens, including the relative benefits and risks of antipsychotics versus mood stabilizers. The exploration of the molecular mechanisms of antipsychotics has helped to shed further light on the underlying neurobiology of bipolar disorder, since these compounds target systems thought to be key to the pathophysiology of bipolar disorder. In addition to modulating monoaminergic neurotransmission, atypical antipsychotics appear to share properties with mood-stabilizing agents known to alter intracellular signal transduction leading to changes in neuronal activity and gene expression. Atypical antipsychotic drugs have been shown to exhibit neuroprotective properties that are mediated by upregulation of trophic and cellular resilience factors. Building on our understanding of existing therapeutics, especially as it relates to underlying disease pathology, newer “plasticity enhancing” strategies hold promise for future treatments of bipolar disorder.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Amrollahi Z, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR et al (2011) Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord 129(1–3):327–331
APA (2002) Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159(4 Suppl):1–50
Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63(1):182–217
Beaulieu JM, Gainetdinov RR, Caron MG (2007) The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 28(4):166–172
Beaulieu JM, Gainetdinov RR, Caron MG (2009) Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49:327–347
Beckford-Ball J (2006) An overview of the new NICE guidelines on bipolar disorder. Nurs Times 102(34):23–24
Benyamina A, Samalin L (2012) Atypical antipsychotic-induced mania/hypomania: a review of recent case reports and clinical studies. Int J Psychiatry Clin Pract 16(1):2–7
Berk M, Dodd S, Kauer-Sant’anna M, Malhi GS, Bourin M, Kapczinski F et al (2007) Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl 434:41–49
Berwaerts J, Lane R, Nuamah IF, Lim P, Remmerie B, Hough DW (2011) Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord 129(1–3):252–260
Blier P, Blondeau C (2011) Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder. J Affect Disord 128(Suppl 1):S3–10
Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M et al (2005) A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 66(1):111–121
Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M (2010) Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 71(2):130–137
Calabrese JR, Elhaj O, Gajwani P, Gao K (2005a) Clinical highlights in bipolar depression: focus on atypical antipsychotics. J Clin Psychiatry 66(Suppl 5):26–33
Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH et al (2005b) A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162(7):1351–1360
Calabrese J, Stet L, Kotari H (2010) Asenapine as adjunctive treatment for bipolar mania: results of a placebo-controlled 12-week study and 40-week extension. Eur Psychiatry (Supplement 1): 1447
Chang KD (2008) The use of atypical antipsychotics in pediatric bipolar disorder. J Clin Psychiatry 69(Suppl 4):4–8
Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH et al (1999) The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 72(2):879–882
Chen G, Henter ID, Manji HK (2010) Translational research in bipolar disorder: emerging insights from genetically based models. Mol Psychiatry 15(9):883–895
Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S et al (2011) Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 378:1306–15
Collo G, Zanetti S, Missale C, Spano P (2008) Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. Eur J Neurosci 28(7):1231–1240
Corya SA, Perlis RH, Keck PE Jr, Lin DY, Case MG, Williamson DJ et al (2006) A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry 67(5):798–806
Councill JH, Tucker ES, Haskell GT, Maynard TM, Meechan DW, Hamer RM et al (2006) Limited influence of olanzapine on adult forebrain neural precursors in vitro. Neuroscience 140(1):111–122
Cousins DA, Young AH (2007) The armamentarium of treatments for bipolar disorder: a review of the literature. Int J Neuropsychopharmacol 10(3):411–431
Cousins DA, Butts K, Young AH (2009) The role of dopamine in bipolar disorder. Bipolar Disord 11(8):787–806
Creson TK, Yuan P, Manji HK, Chen G (2009) Evidence for involvement of ERK, PI3K, and RSK in induction of Bcl-2 by valproate. J Mol Neurosci 37(2):123–134
Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valenti M, Vieta E (2009) Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol 13(1):5–14
Deutch AY, Ongur D, Duman RS (1995) Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus: a novel locus of antipsychotic drug action. Neuroscience 66(2):337–346
Di Benedetto B, Kuhn R, Nothdurfter C, Rein T, Wurst W, Rupprecht R (2011) N-desalkylquetiapine activates ERK1/2 to induce GDNF release in C6 glioma cells: A putative cellular mechanism for quetiapine as antidepressant. Neuropharmacology 62(1):209–16
DiazGranados N, Zarate CA Jr (2008) A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. Curr Psychiatry Rep 10(6):510–519
Dwivedi Y, Pandey GN (1999) Effects of treatment with haloperidol, chlorpromazine, and clozapine on protein kinase C (PKC) and phosphoinositide-specific phospholipase C (PI-PLC) activity and on mRNA and protein expression of PKC and PLC isozymes in rat brain. J Pharmacol Exp Ther 291(2):688–704
Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L et al (2003) The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 23(19):7311–7316
Einat H, Yuan P, Manji HK (2005) Increased anxiety-like behaviors and mitochondrial dysfunction in mice with targeted mutation of the Bcl-2 gene: further support for the involvement of mitochondrial function in anxiety disorders. Behav Brain Res 165(2):172–180
Fraguas D, Correll CU, Merchan-Naranjo J, Rapado-Castro M, Parellada M, Moreno C et al (2010) Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 21(8):621–645
Freyberg Z, Ferrando SJ, Javitch JA (2010) Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 167(4):388–396
Fumagalli F, Molteni R, Bedogni F, Gennarelli M, Perez J, Racagni G et al (2004) Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. Neuroreport 15(13):2109–2112
Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR (2008) Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 28(2):203–209
Gentile S (2007) Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights. CNS Drugs 21(5):367–387
Giese AA (2009) Closing the gap between guidelines for bipolar disorder treatment and clinical practice. Am J Psychiatry 166(11):1205–1206
Goodwin FK (2007) Manic-depressive illness: bipolar disorders and recurrent depression, 2nd edn. Oxford University Press, Oxford
Goodwin FK, Jamison KR (2007) Manic-depressive illness: bipolar disorders and recurrent depression, 2nd edn. Oxford University Press, Oxford
Gould TD, Picchini AM, Einat H, Manji HK (2006) Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets 7(11):1399–1409, Review. PubMed PMID: 17100580
Green W, Patil P, Marsden CA, Bennett GW, Wigmore PM (2006) Treatment with olanzapine increases cell proliferation in the subventricular zone and prefrontal cortex. Brain Res 1070(1):242–245
Hammonds MD, Shim SS (2009) Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. Basic Clin Pharmacol Toxicol 105(2):113–119
He J, Xu H, Yang Y, Zhang X, Li XM (2004) Neuroprotective effects of olanzapine on methamphetamine-induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of Bcl-2 decrease in rats. Brain Res 1018(2):186–192
He J, Xu H, Yang Y, Rajakumar D, Li X, Li XM (2006) The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of Bcl-XL/Bax ratio in the posterior cingulate cortex in rats. Behav Brain Res 168(2):236–242
Hirschfeld RM, Keck PE Jr, Kramer M, Karcher K, Canuso C, Eerdekens M et al (2004) Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 161(6):1057–1065
Hunsberger J, Austin DR, Henter ID, Chen G (2009) The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin Neurosci 11(3):333–348
Hunsberger JG, Machado-Vieira R, Austin DR, Zarate C, Chuang DM, Chen G et al (2011) Bax inhibitor 1, a modulator of calcium homeostasis, confers affective resilience. Brain Res 1403:19–27
Inestrosa NC, Arenas E (2010) Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci 11(2):77–86
Jarskog LF, Gilmore JH, Selinger ES, Lieberman JA (2000) Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol Psychiatry 48(7):641–650
Jarskog LF, Selinger ES, Lieberman JA, Gilmore JH (2004) Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am J Psychiatry 161(1):109–115
Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology 33(10):2303–2312
Jiao S, Li Z (2011) Nonapoptotic function of BAD and BAX in long-term depression of synaptic transmission. Neuron 70(4):758–772
Jonas E (2006) BCL-xL regulates synaptic plasticity. Mol Interv 6(4):208–222
Jonas EA (2009) Molecular participants in mitochondrial cell death channel formation during neuronal ischemia. Exp Neurol 218(2):203–212
Kapur S, Mann JJ (1992) Role of the dopaminergic system in depression. Biol Psychiatry 32(1):1–17
Kato T (2007) Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 61(1):3–19
Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K (2003) Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 160(4):741–748
Keck PE Jr, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM et al (2007) Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 68(10):1480–1491
Keilhoff G, Grecksch G, Bernstein HG, Roskoden T, Becker A (2010) Risperidone and haloperidol promote survival of stem cells in the rat hippocampus. Eur Arch Psychiatry Clin Neurosci 260(2):151–162
Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M (2005) Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry 187:229–234
Kim I, Xu W, Reed JC (2008) Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 7(12):1013–1030
Kim HW, Rapoport SI, Rao JS (2010) Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol Dis 37(3):596–603
Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J (2008) Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. J Clin Psychopharmacol 28(6):601–607
Kusumakar V (2002) Antidepressants and antipsychotics in the long-term treatment of bipolar disorder. J Clin Psychiatry 63(Suppl 10):23–28
Lee R, Kermani P, Teng KK, Hempstead BL (2001) Regulation of cell survival by secreted proneurotrophins. Science 294(5548):1945–1948
Levy B, Manove E (2011) Functional outcome in bipolar disorder: the big picture. Depress Res Treat 2012:949248
Li X, Jope RS (2010) Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology 35(11):2143–2154
Lien R, Flaisher-Grinberg S, Cleary C, Hejny M, Einat H (2008) Behavioral effects of Bcl-2 deficiency: implications for affective disorders. Pharmacol Rep 60(4):490–498
Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, Aprille JR, Dwyer DS, Li XM, Mahadik SP, Duman RS, Porter JH, Modica-Napolitano JS, Newton SS, Csernansky JG (2008) Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 60(3):358–403, Review. Erratum in: Pharmacol Rev. 2008 Dec;60(4):582. PubMed PMID: 18922967
Lipina TV, Kaidanovich-Beilin O, Patel S, Wang M, Clapcote SJ, Liu F et al (2011) Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3. Synapse 65(3):234–248
Luo C, Xu H, Li XM (2004) Post-stress changes in BDNF and Bcl-2 immunoreactivities in hippocampal neurons: effect of chronic administration of olanzapine. Brain Res 1025(1–2):194–202
Macfadden W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C et al (2009) A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 11(8):827–839
Machado-Vieira R, Pivovarova NB, Stanika RI, Yuan P, Wang Y, Zhou R et al (2011) The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder. Biol Psychiatry 69(4):344–352
Maeng S, Hunsberger JG, Pearson B, Yuan P, Wang Y, Wei Y et al (2008) BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments. Proc Natl Acad Sci U S A 105(25):8766–8771
Malkesman O, Austin DR, Tragon T, Henter ID, Reed JC, Pellecchia M, et al (2011) Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants. Mol Psychiatry
Marcus R, Khan A, Rollin L, Morris B, Timko K, Carson W et al (2011) Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 13(2):133–144
McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J (2005) Quetiapine or haloperidol as monotherapy for bipolar mania–a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 15(5):573–585
McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J (2009) Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord 11(8):815–826
McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J (2010) Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 122(1–2):27–38
McQuade R, Marcus R, Sanchez R (2003) Aripiprazole vs placebo in acute mania: safety and tolerability pooled analysis. Paper presented at the 5th International Conference on Bipolar Disorder, Pittsburgh, PA
Merlo S, Canonico PL, Sortino MA (2011) Distinct effects of pramipexole on the proliferation of adult mouse sub-ventricular zone-derived cells and the appearance of a neuronal phenotype. Neuropharmacology 60(6):892–900
Montezinho LP, Castro MM, Duarte CB, Penschuck S, Geraldes CF, Mork A (2006) The interaction between dopamine D2-like and beta-adrenergic receptors in the prefrontal cortex is altered by mood-stabilizing agents. J Neurochem 96(5):1336–1348
Mullen J, Devine N, Sweitzer D (2003) Quetiapine adjunctive therapy for acute mania associated with bipolar disorder (SIAM) Paper presented at the 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA
Nasrallah HA, Hopkins T, Pixley SK (2010) Differential effects of antipsychotic and antidepressant drugs on neurogenic regions in rats. Brain Res 1354:23–29
Newton SS, Duman RS (2007) Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS Drugs 21(9):715–725
Nikolaus S, Antke C, Muller HW (2009) In vivo imaging of synaptic function in the central nervous system: II Mental and affective disorders. Behav Brain Res 204(1):32–66
O'Brien WT, Klein PS (2007) Regulation of glycogen synthase kinase-3 in patients with affective disorders. Biol Psychiatry 61(2):139–141
Pearlson GD, Wong DF, Tune LE, Ross CA, Chase GA, Links JM et al (1995) In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatry 52(6):471–477
Pereira M, Martynhak BJ, Baretta IP, Correia D, Siba IP, Andreatini R (2011) Antimanic-like effect of tamoxifen is not reproduced by acute or chronic administration of medroxyprogesterone or clomiphene. Neurosci Lett 500(2):95–98
Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE Jr (2006) Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 67(4):509–516
Pinsonneault JK, Han DD, Burdick KE, Kataki M, Bertolino A, Malhotra AK et al (2011) Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology 36(8):1644–1655
Popovic D, Reinares M, Amann B, Salamero M, Vieta E (2010) Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology (Berl) 213(4):657–667
Potkin SG, Keck PE Jr, Segal S, Ice K, English P (2005) Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 25(4):301–310
Prieto E, Mico JA, Meana JJ, Majadas S (2010) Neurobiological bases of quetiapine antidepresant effect in the bipolar disorder. Actas Esp Psiquiatr 38(1):22–32
Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V (2010) Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 68(2):156–162
Roh MS, Seo MS, Kim Y, Kim SH, Jeon WJ, Ahn YM et al (2007) Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex. Exp Mol Med 39(3):353–360
Rybakowski J (2005) Maintenance treatment of bipolar disorders. Neuro Endocrinol Lett 26(Suppl 1):49–65
Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL (2002) Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 159(7):1146–1154
Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA et al (2004) Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 6(3):213–223
Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W et al (2006) Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 20(4):536–546
Samuels BA, Hen R (2011) Neurogenesis and affective disorders. Eur J Neurosci 33(6):1152–1159
Scheffer RE, Tripathi A, Kirkpatrick FG, Schultz T (2011) Guidelines for treatment-resistant mania in children with bipolar disorder. J Psychiatr Pract 17(3):186–193
Sklar P, Ripke S, Scott LJ, Andreassen OA, Cichon S, Craddock N et al (2011) Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 43(10):977–83
Smith LA, Cornelius V, Warnock A, Bell A, Young AH (2007) Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 9(4):394–412
Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F (2005) Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 15(1):75–84
Suppes T, Brown E, Schuh LM, Baker RW, Tohen M (2005a) Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data. J Affect Disord 89(1–3):69–77
Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR et al (2005b) The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 66(7):870–886
Suppes T, Vieta E, Liu S, Brecher M, Paulsson B (2009) Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 166(4):476–488
Surja AA, Tamas RL, El-Mallakh RS (2006) Antipsychotic medications in the treatment of bipolar disorder. Curr Drug Targets 7(9):1217–1224
Sutton LP, Rushlow WJ (2011) Regulation of Akt and Wnt signaling by the group II metabotropic glutamate receptor antagonist LY341495 and agonist LY379268. J Neurochem 117(6):973–983
Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A et al (2006) Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 26(6):600–609
Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD et al (2008) Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 28(1):13–20
Tohen M, Vieta E (2009) Antipsychotic agents in the treatment of bipolar mania. Bipolar Disord 11(Suppl 2):45–54
Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG et al (1999) Olanzapine versus placebo in the treatment of acute mania Olanzapine HGEH Study Group. Am J Psychiatry 156(5):702–709
Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG et al (2000) Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study The Olanzipine HGGW Study Group. Arch Gen Psychiatry 57(9):841–849
Tohen M, Chengappa KN, Suppes T, Zarate CA Jr, Calabrese JR, Bowden CL et al (2002) Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 59(1):62–69
Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C et al (2003) Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60(11):1079–1088
Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM et al (2005) Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 162(7):1281–1290
Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R et al (2006) Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 163(2):247–256
Toprac MG, Dennehy EB, Carmody TJ, Crismon ML, Miller AL, Trivedi MH et al (2006) Implementation of the texas medication algorithm project patient and family education program. J Clin Psychiatry 67(9):1362–1372
Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA (2007) Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 68(1):111–119
Vestergaard P (1992) Treatment and prevention of mania: a Scandinavian perspective. Neuropsychopharmacology 7(4):249–259
Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M (2008a) Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 109(3):251–263
Vieta E, T’Joen C, McQuade RD, Carson WH Jr, Marcus RN, Sanchez R et al (2008b) Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 165(10):1316–1325
Vieta E, Nuamah IF, Lim P, Yuen EC, Palumbo JM, Hough DW et al (2010) A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 12(3):230–243
Vieta E, Gunther O, Locklear J, Ekman M, Miltenburger C, Chatterton ML et al (2011) Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 14(8):1029–1049
Wagstaff AJ, Easton J, Scott LJ (2005) Intramuscular olanzapine: a review of its use in the management of acute agitation. CNS Drugs 19(2):147–164
Walburn J, Gray R, Gournay K, Quraishi S, David AS (2001) Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 179:300–307
Weisler R, Dunn J, English P (2003) Ziprasidone in adjunctive treatment of acute bipolar mania: a randomized, placebo-controlled trial. Paper presented at the 16th congress of the European College of Neuro-psychopharmacology, Prague, Czech Republic
Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B (2010) Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 72(11):1452–1464
Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A (2003) Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 182:141–147
Yildiz A, Guleryuz S, Ankerst DP, Ongur D, Renshaw PF (2008) Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 65(3):255–263
Yildiz A, Vieta E, Leucht S, Baldessarini RJ (2011) Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 36(2):375–389
Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9(1):47–59
Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G (2001) The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 276(34):31674–31683
Yuan P, Zhou R, Wang Y, Li X, Li J, Chen G et al (2010) Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. J Affect Disord 124(1–2):164–169
Zarate CA, Manji HK (2009) Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs 23(7):569–582
Zarate CA Jr, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA et al (2007) Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 9(6):561–570
Zhou R, Gray NA, Yuan P, Li X, Chen J, Chen G et al (2005) The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci 25(18):4493–4502
Zupancic ML (2011) Role of atypical antipsychotics in rapid cycling bipolar disorder: a review of the literature. Ann Clin Psychiatry 23(2):141–149
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Singh, J., Chen, G., Canuso, C.M. (2012). Antipsychotics in the Treatment of Bipolar Disorder. In: Gross, G., Geyer, M. (eds) Current Antipsychotics. Handbook of Experimental Pharmacology, vol 212. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-25761-2_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-25761-2_8
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-25760-5
Online ISBN: 978-3-642-25761-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)